1263375-23-0

Basic information

• Product Name: 2,5-Difluoropyridine-4-boronic acid
• Synonyms: 2,5-Difluoropyridine-4-boronic acid
• CAS NO: 1263375-23-0
• Molecular Formula: C₅H₄BF₂NO₂
• Molecular Weight: 158.8985664
• Mol File: 1263375-23-0.mol

Chemical Properties

• Boiling Point: 305.2±52.0 °C(Predicted)
• Appearance: /
• Density: 1.44±0.1 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• PKA: 6.31±0.58(Predicted)
• CAS DataBase Reference: 2,5-Difluoropyridine-4-boronic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2,5-Difluoropyridine-4-boronic acid(1263375-23-0)
• EPA Substance Registry System: 2,5-Difluoropyridine-4-boronic acid(1263375-23-0)

Safety Data

• Hazardous Substances Data: 1263375-23-0(Hazardous Substances Data)

Usage

Uses

Used in Medicinal Chemistry and Pharmaceutical Industry:
2,5-Difluoropyridine-4-boronic acid is utilized as a synthetic building block for the creation of complex organic molecules. Its boronic acid group facilitates the formation of stable complexes with other molecules, which is crucial for the development of novel drugs with improved efficacy and selectivity.
Used in Drug Discovery Research:
In the field of drug discovery, 2,5-Difluoropyridine-4-boronic acid serves as a valuable component due to its ability to influence the reactivity and bioavailability of the compounds it is incorporated into. This makes it an important tool for enhancing the pharmacokinetic and pharmacodynamic properties of potential drug candidates.
Used in Organic Synthesis:
2,5-Difluoropyridine-4-boronic acid is employed as a versatile intermediate in organic synthesis, allowing for the construction of a wide range of chemical entities. Its unique structural features, including the pyridine ring and fluorine atoms, enable the synthesis of diverse compounds with potential applications in various industries, including materials science, agrochemicals, and specialty chemicals.

Upstream product

• 5419-55-6 Triisopropyl borate 
• 84476-99-3 2,5-difluoropyridine 

Relevant articles and documents

PHENYL-HETEROARYL AMINE COMPOUNDS AND THEIR USES

The present invention provides a compound of formula (I): and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds of Formula I, and pharmaceutical compositions comprising such compounds

3-(AMINOARYL)-PYRIDINE COMPOUNDS

The present invention provides a compound of formula (I): and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. Also provided are pharmaceutical compositions containing these compounds and methods of treating a disease or condition mediated by CDK9 using these compounds and compositions.

N-ACYL PYRIDINE BIARYL COMPOUNDS AND THEIR USES

The present invention provides a compound of general formula:wherein Z2-Z6 include one or two nitrogen atoms as described herein, including pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds of Formula I and isomers thereof, and pharmaceutical compositions comprising such compounds.

PYRIDINE BIARYL AMINE COMPOUNDS AND THEIR USES

The present invention provides a compound of formula (I): and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds of Formula I and isomers thereof, and pharmaceutical compositions comprising such compounds.

N-ACYL PYRIMIDINE BIARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS

The present invention provides a compound of the general formula (1): wherein one of X and Y is N and the other is an optionally substituted carbon atom, and Z2-Z5 represent one or two nitrogen atoms, as further described herein, including pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals and as components of pharmaceutical compositions. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds described herein or pharmaceutical compositions comprising such compounds.

PYRIMIDINE BIARYL AMINE COMPOUNDS AND THEIR USES

The present invention provides a pyrimidine compound of formula (I): wherein one of X and Y but not both is N, and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tantomers, diastereomers, deuterated versions, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds of Formula I and isomers thereof, and pharmaceutical compositions comprising such compounds

PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES

The present invention provides a compound of Formula (I) and pharmaceutically acceptable salts thereof. Also provided is a method of using a compound of Formula I for treating a disease or condition mediated by a CDK inhibitor.

HETEROARYL COMPOUNDS AS KINASE INHIBITORS

The present invention provides a compound of Formula (I): and pharmaceutically acceptable salts thereof. Also provided is a method of using a compound of Formula I for treating a disease or condition mediated by a CDK inhibitor